Yvonne Schlaeppi


Ms. Yvonne Schlaeppi joined OpGen’s Board in November 2022. She is Managing Partner of Stratevise LLC, an international strategic advisory firm that she cofounded. From 2016 through its going private in 2019, Ms. Schlaeppi served on the board of directors of Stallergenes Greer plc, a pharmaceutical company traded on the Euronext Paris exchange. From 2014 to 2015, Ms. Schlaeppi served on the board of directors of the allergy immunotherapy company, Greer Laboratories, Inc. Since 2018, Ms. Schlaeppi serves as a director of AstroNova, Inc., a Nasdaq-listed industrial company, which applies data visualization technologies to its hardware and software products for the aerospace and defense, packaging and product identification, and electronic signal data test and measurement sectors, as well as Chair of its Nominating and Governance Committee and a member of its Audit Committee. She is a member of the External Advisory Council to the Channing Division of Network Medicine of Brigham and Women’s Hospital in Boston since 2015.

Prior to founding Stratevise, Ms. Schlaeppi served as General Counsel at three corporate groups, Global Enterprise Technologies, Passport & ID, a high-security document printing solutions provider and systems integrator, Organon BioSciences, a global pharmaceutical, animal health and biotech group based in the Netherlands, and as General Counsel Europe at Johnson Controls, Inc., a NYSE-listed diversified industrial company. She was also a partner and Chair of the International Practice Group at the Boston-based law firm, Palmer & Dodge LLP, where she advised primarily life sciences and technology companies as well as VC’s from outside the US.

Ms. Schlaeppi has been recognized as Directorship Certified by the National Association of Corporate Directors (“NACD”) in 2022 and, from 2017 to 2022, has been recognized annually as a NACD Board Leadership Fellow.

She holds a BA from Princeton University’s Woodrow Wilson School of Public & International Affairs and a JD from Columbia University.